Very late-onset membranous nephropathy secondary to alemtuzumab in a patient with multiple sclerosis
Nefropatía membranosa muy tardía secundaria a alemtuzumab en paciente con esclerosis múltiple
Área salud
Consenso de expertos sobre el uso de alemtuzumab en la práctica clínica diaria en España
Introducción Alemtuzumab es un fármaco de alta eficacia aprobado por la Agencia Europea de Medicamentos como tratamiento modificador de la enfermedad en pacientes con esclerosis múltiple remitente recurrente. Objetivo Elaborar un documento de consenso sobre […]
Área salud
Gadolinium-enhanced brain lesions in multiple sclerosis relapse
Objective To study the clinico-radiological paradox in multiple sclerosis (MS) relapse by analyzing the number and location of gadolinium-enhanced (Gd+) lesions on brain MRI before methylprednisolone (MP) treatment. Methods We analyzed brain MRI from 90 […]
Área salud
Fear of Relapse Scale: Spanish version and psychometric characteristics in a sample of patients with Relapsing-Remitting multiple sclerosis
Introduction Relapses are a hallmark of multiple sclerosis, being a characteristic feature of relapsing-remitting multiple sclerosis (RRMS). The occurrence of a relapse constitutes a source of significant discomfort that impacts all domains of daily life […]